You are here

  • Home
  • Archive
  • Volume 9, Issue 8
  • Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids

Article metrics

Article menu

This article has a correction. Please see:

XML
Oncolytic and local immunotherapy
Original research
Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids

 

Online download statistics by month:

Online download statistics by month: August 2021 to March 2024

AbstractFullPdf
Aug 202110851088306
Sep 2021383384211
Oct 2021227227112
Nov 202117317382
Dec 202116217674
Jan 202213015395
Feb 2022737858
Mar 202211612675
Apr 2022126150121
May 202296127106
Jun 202212915489
Jul 202286123101
Aug 20229410677
Sep 20229911094
Oct 202211312379
Nov 202211812964
Dec 2022697153
Jan 202312812836
Feb 202310611154
Mar 202310610962
Apr 202310210456
May 202310812871
Jun 20239810053
Jul 2023666762
Aug 2023878843
Sep 2023666850
Oct 2023646424
Nov 2023606033
Dec 2023717234
Jan 20249010251
Feb 202411911934
Mar 2024105109124
Total465549272584